SORRENTO THERAPEUTICS, INC. (NASDAQ:SRNE) Files An 8-K Regulation FD Disclosure

SORRENTO THERAPEUTICS, INC. (NASDAQ:SRNE) Files An 8-K Regulation FD Disclosure
Item 7.01. Regulation FD Disclosure.

On June 12, 2019, Sorrento Therapeutics, Inc. issued the press release filed herewith as Exhibit 99.1.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibit.

99.1 Press Release, dated June 12, 2019.


Sorrento Therapeutics, Inc. Exhibit
EX-99.1 2 tv523437_ex99-1.htm EXHIBIT 99.1   Exhibit 99.1       FOR IMMEDIATE RELEASE   June 12,…
To view the full exhibit click here

Story continues below

About SORRENTO THERAPEUTICS, INC. (NASDAQ:SRNE)

Sorrento Therapeutics, Inc. is a biopharmaceutical company. The Company is engaged in the discovery, acquisition, development and commercialization of drug therapeutics. Its primary therapeutic focus is oncology, including the treatment of chronic cancer pain. It is also developing therapeutic products for other indications, including immunology and infectious diseases. Its products in the pipeline include Chimeric Antigen Receptor-T Cell (CAR-T) programs, resiniferatoxin (RTX), and biosimilar/biobetter antibodies clinical development programs. Its pipeline also includes preclinical fully human therapeutic monoclonal antibodies (mAbs), including biosimilars/biobetters, fully human anti-PD-L1 and anti-PD-1 checkpoint inhibitors derived from its G-MAB library platform, antibody drug conjugates (ADCs), bispecific antibodies (BsAbs), as well as CAR-T and Chimeric Antigen Receptor Natural Killer (NK) cells (CAR. NK) for adoptive cellular immunotherapy.

An ad to help with our costs